Daiichi planning NDA for pexidartinib on Phase III TGCT data

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported data from 120 patients with symptomatic advanced tenosynovial giant cell tumors (TGCT) in the Phase III ENLIVEN trial showing that oral pexidartinib (PLX3397) led to an overall response

Read the full 346 word article

User Sign In